Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10361958" target="_blank" >RIV/00216208:11110/17:10361958 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10361958

Výsledek na webu

<a href="http://dx.doi.org/10.1177/1756285616671887" target="_blank" >http://dx.doi.org/10.1177/1756285616671887</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1756285616671887" target="_blank" >10.1177/1756285616671887</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Popis výsledku v původním jazyce

Daclizumab is a humanized monoclonal antibody that binds to the a subunit (CD25) of the interleukin- 2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrastenhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon beta 1a. This review summarizes the development of and clinical experience with daclizumab in MS.

Název v anglickém jazyce

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Popis výsledku anglicky

Daclizumab is a humanized monoclonal antibody that binds to the a subunit (CD25) of the interleukin- 2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrastenhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon beta 1a. This review summarizes the development of and clinical experience with daclizumab in MS.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Therapeutic Advances in Neurological Disorders

ISSN

1756-2856

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

67-75

Kód UT WoS článku

000396377100006

EID výsledku v databázi Scopus

2-s2.0-85008482394